Simplify Propel Opportunities ETF (SURI)
NYSEARCA: SURI · Real-Time Price · USD
17.70
-0.20 (-1.09%)
Jul 28, 2026, 10:30 AM EDT - Market open
-1.09% (1D)
| Assets | $76.70M |
| Expense Ratio | 2.56% |
| PE Ratio | n/a |
| Shares Out | 4.29M |
| Dividend (ttm) | $2.72 |
| Dividend Yield | 15.20% |
| Ex-Dividend Date | Jun 25, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | n/a |
| Volume | 2,626 |
| Open | 17.82 |
| Previous Close | 17.90 |
| Day's Range | 17.70 - 17.99 |
| 52-Week Low | 14.70 |
| 52-Week High | 18.50 |
| Beta | 1.14 |
| Holdings | 36 |
| Inception Date | Feb 7, 2023 |
About SURI
Fund Home PageThe Simplify Propel Opportunities ETF (SURI) is an exchange-traded fund that mostly invests in target outcome asset allocation. The fund employs an actively managed, multi-asset strategy that focuses on equity and debt securities of companies in the healthcare sector. The fund selects securities believed to be attractive investment opportunities SURI was launched on Feb 7, 2023 and is issued by Simplify.
Asset Class Asset Allocation
Category Health
Stock Exchange NYSEARCA
Ticker Symbol SURI
ETF Provider Simplify
Top 10 Holdings
82.85% of assets| Name | Symbol | Weight |
|---|---|---|
| Plains GP Holdings, L.P. | PAGP | 43.89% |
| Achieve Life Sciences, Inc. | ACHV | 11.39% |
| Milestone Pharmaceuticals Inc. | MIST | 5.07% |
| Delcath Systems, Inc. | DCTH | 4.16% |
| ACHIEVE LIFE SCIENCES I WTS 30JUN30 | n/a | 3.91% |
| Phathom Pharmaceuticals, Inc. | PHAT | 3.72% |
| Corcept Therapeutics Incorporated | CORT | 3.29% |
| Cash | Cash | 2.81% |
| Celldex Therapeutics, Inc. | CLDX | 2.44% |
| Abeona Therapeutics Inc. | ABEO | 2.18% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 25, 2026 | $0.680 | Jun 30, 2026 |
| Mar 26, 2026 | $0.680 | Mar 31, 2026 |
| Dec 23, 2025 | $0.680 | Dec 31, 2025 |
| Sep 25, 2025 | $0.680 | Sep 30, 2025 |
| Jun 25, 2025 | $0.680 | Jun 30, 2025 |
| Mar 26, 2025 | $0.680 | Mar 31, 2025 |
Performance
SURI had a total return of 36.15% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.88%.
